Pembrolizumab has been shown to significantly benefit patients with MSI-high/dMMR metastatic colorectal cancer. In a presentation to the 2020 ASCO Virtual Scientific Program, Professor Thierry Andre from the Sorbonne University said the checkpoint inhibitor should now be the standard of care in first line therapy. The KEYNOTE-177 study compared outcomes in 307 patients from 23 ...
KEYNOTE-177 supports pembrolizumab in MSI-high colorectal cancer
By Mardi Chapman
2 Jun 2020